NCT00533793已完成2 期
A Phase II Randomized, Controlled, Open-labeled (Dose-blinded) Dose Finding Study of the Safety and Efficacy of I-040202 in the Treatment of Patients With Acute Open Tibial Shaft Fractures
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 201
- 试验地点
- 98
- 主要终点
- Clinical Criteria:weight bearing,red.pain,walking without aid;lack of need for surg. interv. fracture site;Radiogr. crit.:Cortical bridging,disintegration/disappearance fracture lines,absence of signs for complications(infection,malunion)
研究概览
简要总结
A phase 2, prospective, randomized, controlled, open-label (dose-blinded), parallel group, international multi-center study. The study will consist of four treatment groups - one control group (SoC) and three I-040202 groups receiving SoC plus 0.133 mg/mL, 0.4 mg/mL or 1.0 mg/mL I-040202.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eligible patients must meet all of the following inclusion criteria:
- •patients with an acute open fracture of the tibial shaft secondary to trauma assessed by medical examination and current radiographs indicated for open fracture reduction and internal fixation using osteosynthesis plates or intra-medullary nails
- •soft tissue management (if medically warranted, eg. debridement, irrigation, application of antibiotics) performed according to local hospital practice no later than 24h after the trauma
- •male and female patients >= 18 years
- •body mass index (BMI) 16-33 (minimum body weight 50 kg, maximum 140 kg)
- •females of child-bearing potential must be willing to undergo a pregnancy test (urine) prior to treatment start (at screening)
- •females of child-bearing potential randomized in the intervention group must agree to have acceptable contraception for at least 3 months after receiving the study medication.
- •Acceptable contraceptive measures are:
- •Hormonal types of birth control with a failure rate of less than 1% per year (such as implants, injections, combined oral contraceptives, patches or other methods) or copper IUDs or other IUDs with a failure rate of less than 1% per year, AND
- •An additional barrier type of birth control measure (such as condoms, diaphragms, cervical caps, etc.) Sterilized women and abstinent women of child-bearing potential will not be required to take contraceptive measures
- •willingness and ability to understand, participate and comply with the study requirements
- •patient be able to give consent personally and sign the Informed Consent Form.
- •Exclusion criteria:
- •Patients will be not eligible if they meet one of the following exclusion criteria:
- •IIIc open fracture according to the Gustilo-Anderson classification
- •tibial defects requiring bone-grafting (e.g. large segmental defects)
- •duration from trauma to surgery longer than 14 days
- •concomitant acute bone injuries and/or major skin or other significant injuries that in the opinion of the investigator would interfere with the tibial shaft fracture healing process
- •concomitant ipsilateral tibial fractures other than in the diaphyseal region
- •evidence of immune suppression
- •suspected or known hypersensitivity to the study medication or components of it
- •evidence of hypercalcemia
- •hyperparathyroidism
- •on treatment and/or planned treatment with products containing PTH (e.g. Forteo)
- •pregnant or lactating females
- •participation in another clinical trial within the last 3 months
- •active or past history of malignant tumor
- •history or evidence for any hereditary or acquired chronic metabolic bone disease other than primary osteoporosis.
- •history or evidence for any clinically relevant organ failure or any other relevant medical condition that, in the opinion of the investigator, will relevantly interfere with the assessment of study outcome or will impose hazard to the patient if study therapy will be initiated
- •known history of allergy to anaesthetics
- •evidence of moderate or severe renal failure (serum creatinine > 3.0 times ULN, NCI CTC grades 3 and 4)
- •known history of allergic thrombocytopenia (type II) induced by heparin
- •inexplicable elevations of alkaline phosphatase or alkaline phosphatase > 5.0 times ULN, NCI CTC grades 3 and 4
- •prior external beam or implant radiation therapy to the skeleton
排除标准
- 未提供
结局指标
主要结局
Clinical Criteria:weight bearing,red.pain,walking without aid;lack of need for surg. interv. fracture site;Radiogr. crit.:Cortical bridging,disintegration/disappearance fracture lines,absence of signs for complications(infection,malunion)
时间窗: short term follow-up: 6 months; long term follow-up: additional 6 months (total duration of 1 year)
次要结局
- Prop. patients healed 3,9,12 mths after T0; prop. time, extent radiogr. union for 2,3,4,5,6,9,12 mths after T0; Eval.:6 and 12 mths; prop./invasiven. sec. interv. due to persistent non-union within 6,12 mths after T0.(short term follow-up: 6 months; long term follow-up: additional 6 months (1 year))
研究者
研究点 (98)
Loading locations...
相似试验
尚未招募
2 期
Study to Evaluate Safety and Efficacy of EG-301 in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMDNCT05170048Evergreen Therapeutics, Inc.90
进行中（未招募）
1 期
A phase II randomized, controlled, open-labeled (dose-blinded) dose finding study of the safety and efficacy of I-040202 in the treatment of patients with acute open tibial shaft fractures - N/AAcute open tibial shaft fracturesMedDRA version: 9.1Level: HLTClassification code 10024956Term: Lower limb fracturesEUCTR2006-005093-40-SKKuros Biosurgery AG200
进行中（未招募）
不适用
A phase II randomized, controlled, open-labeled (dose-blinded) dose finding study of the safety and efficacy of I-040202 in the treatment of patients with acute open tibial shaft fractures - N/AEUCTR2006-005093-40-HUKuros Biosurgery AG200
进行中（未招募）
不适用
A phase II randomized, controlled, open-labeled (dose-blinded) dose finding study of the safety and efficacy of I-040202 in the treatment of patients with acute open tibial shaft fractures - N/AAcute open tibial shaft fracturesMedDRA version: 9.1Level: HLTClassification code 10024956Term: Lower limb fracturesEUCTR2006-005093-40-CZKuros Biosurgery AG200
进行中（未招募）
不适用
A phase II randomized, controlled, open-labeled (dose-blinded) dose finding study of the safety and efficacy of I-040202 in the treatment of patients with acute open tibial shaft fractures - N/AAcute open tibial shaft fracturesMedDRA version: 9.1Level: HLTClassification code 10024956Term: Lower limb fracturesEUCTR2006-005093-40-BGKuros Biosurgery AG200